74 results about "Infectious arthritis" patented technology

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention discloses medicinal liquor for treating rheumatic arthritis and chronic infectious arthritis, which comprises the following raw materials in parts by weight: 33-38 parts of Chinese parsnip root, 8-13 parts of asarum, 28-33 parts of the root of bidentate achyranthes, 28-33 parts of ligusticum sinense oliver, 28-33 parts of notopterygium root, 28-33 parts of radix angelicae pubescentis, 23-28 parts of prepared monkshood, 28-33 parts of cassia twig, 28-33 parts of pawpaw, 28-33 parts of radix clematidis, 28-33 parts of cortex acanthopanacis, 28-33 parts of semen coicis, 28-33 parts of corydalis tuber, 28-33 parts of large-leaved gentian, 4-9 parts of long-noded pit viper, 28-33 parts of the root of fangji, 28-33 parts of rhizoma typhonii, 28-33 parts of ligusticum wallichii, 28-33 parts of zaocys dhumnade, and 7000-8000 parts of 50-60-degree white wine. The medicinal liquor disclosed by the invention has the advantages of being low in cost, high in curative rate and free from toxic and side effects; stimulation of the existing medicines on gastric mucosa is overcome; simultaneously, the medicinal liquor disclosed by the invention also has the functions of tonifying liver and kidney.

The invention discloses the structure of four novel bakkenolide compounds extracted from Petasites tricholobus Franch. having a formula (1), the process for extraction and separation, and the use of the compounds in preparing medicament for the treatment and prevention of diseases possibly related to theramine and/or leukotrienes constituents, including asthma, allergic rhinitis, nasal sinusitis, conjunctivitis, food allergy, psoriasis, urticaria, pruritus, eczema, chronic infectious arthritis, enteropathy, nervous disease and otitis.

The invention relates to a Chinese medicinal capsule for treating chronic infectious arthritis and rigid rachitis and process for preparation, wherein the raw materials include agkistrodon acutus, black-tail snake, black ants, ginseng, asaryl, scorpion, earthworm, large-leaf gentian root, seed of nuxvomica, dried rehmannia root, eucommia bark and epimeddium.

The present invention relates to compounds of Formula (I),

methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

The invention relates to a medicinal oral preparation, i.e., a saussurea involucrata drop pill for treating rheumatic arthritis, chronic infectious arthritis and dysmenorrheal, which has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, less toxic and side effects, higher medicinal content, smaller amount of administration, accurate administration dosage, easy administration, low price, and facilitated carrying. The medicine is prepared through the conventional drop pill preparing process.

The invention discloses an integrin blocker polypeptide as well as a preparation method and application thereof, and belongs to the field of biopharmacy. The integrin blocker polypeptide only has 9 to 17 amino acids from the polypeptide I to the polypeptide X, and is synthesized by using a solid-phase synthesis method, so that the integrin blocker polypeptide also has an in-vivo immune protection function and can be used for treating arthritis even the number of the amino acids in the integrin blocker polypeptide is reduced. The integrin blocker polypeptide has the function of inhibiting neovascularization and has the activity of inhibiting endothelial cell migration so as to prevent and treat diseases relevant to blood vessels and inflammations comprising oculopathy relevant to neovascularization. The integrin blocker polypeptide has the high anti-tumor activity to various types of tumors, so that the cost is greatly lowered. The integrin blocker polypeptide has the good function for treating chronic infectious arthritis, so that the adaptability and the applicable diseases of the integrin blocker polypeptide are increased. Thus, the social and economic values of the integrin blocker polypeptide are enlarged.

An alkannin derivative as immuno-suppressive agent and its metallic complex compound with a chemical constitution formulas III and IV disclosed in the specification, wherein in formula III, R is C1-6 saturated, unsaturated and aromatic acyl, in formula IV, R is hydrogen, C1-6 saturated, unsaturated and aromatic acyl, M is metallic Cu, Ca, Zn. The present invention realizes immunological suppression effect, thus can be used for treating diseases relating to human body autoimmune including chronic infectious arthritis, scleredema, lupus erythematosus, HIV infection and malignant tumor.

The invention discloses the use of spicebush root alkaloid in preparing medicament for treating chronic infectious arthritis and other immune diseases. Animal tests show that, the spicebush root alkaloid can substantially alleviate the degree of mouse joint pathological changes, and lower the mouse feet tumefaction degree caused by arthralgia due to wind-cold-dampness.

The invention relates to the application of ginkgolic acid in treating arthritis. The ginkgolic acid comprises ginkgoic acid, ginkgol, ginkgoic diphenol and the like and can be obtained from the extracts of the parts of the leaves, the fruits, the episperms, the rhizomes and the like of gingkoes by a chemical separation method. The arthritis is rheumatoid arthritis, chronic infectious arthritis, gouty arthritis, osteoarthritis and the like. A medicine, a medical appliance or a disinfector preparation which contains the ginkgolic acid and is used for treating the arthritis contains 0.001 to 80 percent of ginkgolic acid (calculated according to weight percent) and an external preparation substrate or an acceptable carrier which is generally used pharmaceutically; and the preparation is any external preparation formulation which is given pharmaceutically. The research of a pharmacological experiment shows that the ginkgolic acid has the favorable actions of improving arthrocele, relieving joint injury and suppressing local inflammation to an animal model with the arthritis. Clinical trial shows that the ginkgolic acid has an obvious therapeutic action to each type of arthritis, and the effective rate reaches more than 90 percent. In use, the ginkgolic acid is safe and has no side effect.

The invention relates to a formula for treating and preventing arthritis, synovitis and other orthopaedic diseases and complicating diseases and discloses a main compound extracted from mangosteen:Garcinia mangostana. In the main compound, alpha-mangostin serving as a main ingredient is used in combination with various common filters in pharmaceuticals industry to prepare various proper formulations including tablets, capsules, powders, suppositories and the like for oral or external use for treating and preventing arthritis diseases such as rheumatoid arthritis, chronic infectious arthritis, post-traumatic arthritis, osteoarthritis and purulent arthritis as well as complicating diseases of the arthritis diseases such as inflammations of finger joints, metacarpophalangeal joints, wrist joints, elbow joints, shoulder joints, knee joints, spondyl joints, ankle joints, metatarsophalangeal joints and other joints. The alpha-mangostin content of the product of the invention is between 0.1 and 99.9 percent. The product manufactured by the formula can relieve the various inflammations and has certain analgesic effect. The product can be used alone or in combination with other substances.

The invention relates to a monoclonal antibody capable of neutralizing CYR61 and applications thereof and a hybrid tumor capable of generating the monoclonal antibody. The technical scheme adopted by the invention relates to the monoclonal antibody secreted by the mouse anti-human CYR61 monoclonal antibody hybrid tumor CGMCC No.2766 or CGMCC No.2767, and the applications of the monoclonal antibody to preparation of a medicament for treating rheumatic disease, wherein the rheumatic disease is the chronic infectious arthritis. The invention has the advantages that: (1) the self-prepared monoclonal antibody can research pathogenesis of CYR61 in rheumatoid arthritis and can accurately position the expression of CYR61 and detect the CYR61 level of the blood serum and the lesion sites (such as joints); (2) the monoclonal antibody can be used for preparing a detection kit so as to distinguish clinical diagnostics of osteoarthritis and rheumatoid arthritis; and (3) the monoclonal antibody also can search the combination epitope where the CYR61 on the surface of the synovium and in the synovial of the rheumatoid arthritis patient can be neutralized, and provides the screening basis for preparing a humanized antibody which can neutralize the CYR61 in the next step.

The invention relates to medicinal liquor for treating rheumatic arthritis. The medicinal liquor for treating rheumatic arthritis is prepared from 30 grams of safflower, 30 grams of Chinese angelica, 50 grams of long-noded pit viper, 30 grams of scorpion, 25 grams of frankincense, 40 grams of ground beeltle, 40 grams of eucommia bark, 40 grams of ningpo yam rhizome, 40 grams of divaricate saposhnikovia root, 40 grams of clematis root and 40 grams of mulberry twig. The accuracy of weight of the medicaments is +/-10 percent. The medicinal liquor for treating rheumatic arthritis is mainly used for treating rheumatic arthritis, also has good treatment effect on osteoarthritis and chronic infectious arthritis, avoids toxic and side effects, and is remarkable in treatment effect and high in cure rate.

The invention discloses a traditional Chinese medicine for treating chronic infectious arthritis, belonging to the technical field of treatment of orthopedics and traumatology. The traditional Chinese medicine is characterized by being prepared from the Chinese medical herbs in parts by weight: 15-20 parts of Chinese angelica, 15-20 parts of rhizoma rehmannia, 10-15 parts of cocklebur fruit, 20-25 parts of garter snake, 10-15 parts of eupolyphaga, 3-5 parts of scorpio, 10-15 parts of roasted squamamanitis into puffy with sand, 30-35 parts of rhizoma dioscoreae nipponicae, 20-25 parts of epimedium, 25-30 parts of caulis spatholobi, 15-20 parts of cortex erythrinae, 5-8 parts of dung beetle, 2-4 parts of centipede and 15-20 parts of medicinal cyathula root. According to the pathological mechanism principle of the chronic infectious arthritis and the reason causing the chronic infectious arthritis, a pure Chinese medicine formula is adopted, an oral liquid, or powder, or a tablet, or a capsule is prepared through extracting effective components; and an externally applied agent plaster can also be prepared. After the traditional Chinese medicine is orally taken, the chronic infectious arthritis can be effectively treated, and an ideal effect is achieved.